RGNX

6.29

5.70% -0.38

Handel nachbörslich: 6.29

Regenxbio Inc (RGNX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$6.67

Offen:

$6.45

24-Stunden-Volumen:

1.09M

Relative Volume:

1.22

Marktkapitalisierung:

$310.87M

Einnahmen:

$89.04M

Nettoeinkommen (Verlust:

$-241.08M

KGV:

-1.1958

EPS:

-5.26

Netto-Cashflow:

$-194.72M

1W Leistung:

-19.67%

1M Leistung:

+6.25%

6M Leistung:

-35.29%

1J Leistung:

-67.15%

1-Tages-Spanne:

$6.26

$6.545

1-Wochen-Bereich:

$6.26

$7.46

52-Wochen-Spanne:

$5.66

$19.88

Regenxbio Inc Stock (RGNX) Company Profile

Firmenname

Regenxbio Inc

Sektor

Healthcare (1162)

Branche

Biotechnology (673)

Telefon

240-552-8181

Adresse

9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD

Mitarbeiter

344

Twitter

@REGENXBIO

Nächster Verdiensttermin

2025-03-04

Neueste SEC-Einreichungen

RGNX's Discussions on Twitter

Vergleichen Sie RGNX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RGNX Regenxbio Inc	6.29	310.87M	89.04M	-241.08M	-194.72M	-5.26
VRTX Vertex Pharmaceuticals Inc	474.62	121.88B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	573.45	62.69B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	555.11	33.86B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.74	30.51B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	238.51	25.69B	3.81B	-644.79M	-669.77M	-6.24

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-11	Herabstufung	Goldman	Buy → Neutral
2025-02-07	Fortgesetzt	Raymond James	Outperform
2024-11-15	Fortgesetzt	Morgan Stanley	Overweight
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-06-07	Eingeleitet	Goldman	Buy
2024-03-11	Eingeleitet	H.C. Wainwright	Buy
2024-03-08	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2024-03-06	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-02-21	Fortgesetzt	Raymond James	Outperform
2023-11-01	Eingeleitet	Stifel	Buy
2023-06-02	Eingeleitet	Robert W. Baird	Outperform
2022-06-23	Eingeleitet	Berenberg	Buy
2021-12-15	Eingeleitet	Wedbush	Neutral
2021-10-19	Fortgesetzt	Morgan Stanley	Overweight
2021-01-06	Hochstufung	Raymond James	Outperform → Strong Buy
2020-12-16	Eingeleitet	UBS	Buy
2020-06-25	Fortgesetzt	BofA/Merrill	Buy
2020-05-13	Eingeleitet	RBC Capital Mkts	Sector Perform
2019-08-20	Hochstufung	SVB Leerink	Underperform → Mkt Perform
2019-06-18	Bestätigt	Chardan Capital Markets	Buy
2019-06-14	Fortgesetzt	Raymond James	Outperform
2019-06-05	Bestätigt	Chardan Capital Markets	Buy
2019-02-25	Hochstufung	Evercore ISI	In-line → Outperform
2019-02-05	Hochstufung	Raymond James	Outperform → Strong Buy
2018-12-17	Bestätigt	Chardan Capital Markets	Buy
2018-11-08	Bestätigt	BofA/Merrill	Neutral
2018-08-08	Bestätigt	Chardan Capital Markets	Buy
2018-07-23	Herabstufung	BofA/Merrill	Buy → Neutral
2018-07-10	Bestätigt	Chardan Capital Markets	Buy
2018-05-09	Bestätigt	Barclays	Overweight
2018-04-09	Bestätigt	Chardan Capital Markets	Buy
2018-03-12	Herabstufung	Evercore ISI	Outperform → In-line
2018-02-13	Eingeleitet	Mizuho	Neutral
2017-11-09	Fortgesetzt	Morgan Stanley	Overweight

Alle ansehen

Regenxbio Inc Aktie (RGNX) Neueste Nachrichten

Apr 02, 2025

When (RGNX) Moves Investors should Listen - news.stocktradersdaily.com

Apr 02, 2025

Mar 31, 2025

Clear Street sets Regenxbio stock Buy rating, $50 target By Investing.com - Investing.com Australia

Mar 31, 2025

Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing - insights.citeline.com

Mar 21, 2025

RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating - TipRanks

Mar 21, 2025

Mar 20, 2025

REGENXBIO’s DMD Gene Therapy RGX-202 Generates Microdystrophin Expression in Additional Patients Treated in Phase 1/2 Trial - CGTLive™

Mar 20, 2025

Regenxbio Rises After Duchenne Update And Sarepta Safety Scare - insights.citeline.com

Mar 20, 2025

Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN

Mar 20, 2025

Regenxbio’s RGX-202 continues to show promise in DMD - The Pharma Letter

Mar 20, 2025

Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old - Clinical Trials Arena

Mar 20, 2025

Regenxbio stock target raised to $29 at Raymond James By Investing.com - Investing.com Canada

Mar 20, 2025

Mar 19, 2025

REGENXBIO reports promising gene therapy trial results By Investing.com - Investing.com South Africa

Mar 19, 2025

Baird maintains Regenxbio stock outperform rating, $39 target By Investing.com - Investing.com South Africa

Mar 19, 2025

Baird maintains Regenxbio stock outperform rating, $39 target - Investing.com

Mar 19, 2025

Regenxbio stock target raised to $29 at Raymond James - Investing.com India

Mar 19, 2025

Regenxbio up 4% following additional data on Duchenne gene therapy asset - MSN

Mar 19, 2025

Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial - Benzinga

Mar 19, 2025

Regenxbio Says New Data Support Potential Gene Therapy for Duchenne Muscular Dystrophy - MarketScreener

Mar 19, 2025

REGENXBIO reports promising gene therapy trial results - Investing.com India

Mar 19, 2025

REGENXBIO: New Interim Data Reinforces Potential Of RGX-202Quick Facts - Nasdaq

Mar 19, 2025

Breakthrough: REGENXBIO DMD Gene Therapy Achieves Unprecedented 122% Protein Expression - StockTitan

Mar 19, 2025

Mar 18, 2025

Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha

Mar 18, 2025

Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements - Investing.com

Mar 18, 2025

Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements By Investing.com - Investing.com Canada

Mar 18, 2025

Mar 17, 2025

H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy By Investing.com - Investing.com Philippines

Mar 17, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner - Yahoo Finance

Mar 17, 2025

H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy - Investing.com India

Mar 17, 2025

Mar 15, 2025

Regenxbio completes its BLA filing for first potential gene therapy for MPS II - The Pharma Letter

Mar 15, 2025

Mar 14, 2025

REGENXBIO Earnings Call Highlights Strategic Progress - TipRanks

Mar 14, 2025

Earnings call transcript: Regenxbio Q4 2024 beats EPS forecast, stock surges - Investing.com Australia

Mar 14, 2025

Stifel maintains Buy on Regenxbio stock, $40 target By Investing.com - Investing.com South Africa

Mar 14, 2025

Stifel maintains Buy on Regenxbio stock, $40 target - Investing.com India

Mar 14, 2025

A Glimpse Into The Expert Outlook On Regenxbio Through 5 Analysts - Benzinga

Mar 14, 2025

Regenxbio Inc earnings beat by $0.12, revenue fell short of estimates - Investing.com Australia

Mar 14, 2025